Page last updated: 2024-09-05
sb 216763 and Hypoxia
sb 216763 has been researched along with Hypoxia in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bertolotti, P; Carruba, MO; De Simoni, MG; Delbarba, A; Dossena, M; Nisoli, E; Perego, C; Ragni, M; Spano, P; Valerio, A | 1 |
Other Studies
1 other study(ies) available for sb 216763 and Hypoxia
| Article | Year |
|---|---|
Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production.
Topics: Animals; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; DNA-Binding Proteins; DNA, Mitochondrial; Dose-Response Relationship, Drug; Embryo, Mammalian; Enzyme Inhibitors; Glucose; Glycogen Synthase Kinase 3; High Mobility Group Proteins; Hypoxia; Indoles; Infarction, Middle Cerebral Artery; L-Lactate Dehydrogenase; Maleimides; Mice; Mitochondria; Mutation; Neurons; Nuclear Respiratory Factor 1; Organelle Biogenesis; Reactive Oxygen Species; RNA, Messenger; Transfection | 2011 |